Impact of type 2 targeting biologics on acute exacerbations of chronic rhinosinusitis
| Autor: | Margaret S. Kim, Whitney W. Stevens, Robert C. Kern, Stephanie Shintani Smith, Leslie C. Grammer, Chen Yeh, Elizabeth Kudlaty, Anju T. Peters, Amina Guo, Ravi Kalhan, Gayatri B. Patel, Caroline P.E. Price, Kevin C. Welch, Sharon R. Rosenberg, Kris G. McGrath, David B. Conley, Bruce K. Tan, Robert P. Schleimer |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty Omalizumab chemistry.chemical_compound Nasal Polyps Reslizumab Adrenal Cortex Hormones Internal medicine medicine Humans Immunology and Allergy Nasal polyps Sinusitis Retrospective Studies Rhinitis Asthma Biological Products business.industry Antibodies Monoclonal Retrospective cohort study Articles General Medicine Benralizumab medicine.disease Dupilumab Anti-Bacterial Agents chemistry Chronic Disease Disease Progression Quality of Life business Mepolizumab medicine.drug |
| Zdroj: | Allergy Asthma Proc |
| ISSN: | 1088-5412 |
| DOI: | 10.2500/aap.2021.42.210058 |
| Popis: | Background: Acute exacerbations of chronic rhinosinusitis (AECRS) are associated with significant morbidity and decreased quality of life. There are sparse data assessing the real-world impact of biologics on AECRS. Objectives: We sought to determine the impact of type 2‐targeting biologics on the frequency of medication use for AECRS episodes. Methods: Antibiotic and/or systemic corticosteroid courses for AECRS were identified in a retrospective study from November 2015 to February 2020, at a single academic health system. The estimated yearly rates for antibiotic and corticosteroid courses were evaluated before and after initiation of type 2 biologics. Results: One-hundred and sixty-five patients with chronic rhinosinusitis (CRS) had received either omalizumab (n = 12), mepolizumab (n = 42), benralizumab (n = 44), dupilumab (n = 61), or reslizumab (n = 6). Seventy percent had CRS with nasal polyps, and 30% had CRS without nasal polyps. All the patients had asthma. When all the biologics were combined, the estimated yearly rate for antibiotics for AECRS decreased from 1.34 (95% confidence interval [CI], 1.12‐1.59) to 0.68 (95% CI, 0.52‐0.88) with biologic use (49% reduction, p < 0.001). Those with frequent AECRS (three or more courses of antibiotics in the 1 year before biologic use) had a larger degree of reduction, with an estimated yearly rate of 4.15 (95% CI, 3.79‐4.55) to 1.58 (95% CI, 1.06‐2.35) with biologic use (n = 27; 62% reduction; p < 0.001). Within the total cohort, the estimated yearly rate for systemic corticosteroids for AECRS decreased from 1.69 (95% CI, 1.42‐2.02) to 0.68 (95% CI, 0.53‐0.88) with biologic use (60% reduction; p < 0.001). Conclusion: Type 2‐targeting biologics reduced medication use for AECRS. This suggested that biologics may be a therapeutic option for patients with frequent AECRS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|